Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin.
We performed a double-blind, placebo-controlled, crossover trial of sulfamethoxazole-trimethoprim (S-T) in 8 patients with Machado-Joseph disease (MJD), and measured the blood and cerebrospinal fluid levels of biopterins, biogenic amines or metabolites, and folate. The clinical results were as follows; mild improvements of hyperreflexia of knee jerks and of rigospasticity of the legs during S-T treatment period. In addition, S-T significantly reduced the times of 8 motor activities on the timed tests. The biochemical results showed that basal levels of all biopterins and homovanillic acid in the cerebrospinal fluid (CSF) were reduced to less than half the levels of those of controls with other neurological diseases. After S-T treatment, total and oxidized form of biopterins in the CSF increased significantly. Therefore, S-T may be effective to neurologic deficits through its mechanism of increasing the level of brain biopterins.
Sakai
T
T
Department of Neurology, National Chikugo Hospital, Fukuoka, Japan.
Matsuishi
T
T
Yamada
S
S
Komori
H
H
Iwashita
H
H
D000328:Adult; D001708:Biopterins / Q000134:cerebrospinal fluid*; D004311:Double-Blind Method; D006801:Humans; D017827:Machado-Joseph Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D001708:Biopterins; D015662:Trimethoprim, Sulfamethoxazole Drug Combination